CURLF vs NAGE
Curaleaf Holdings, Inc. and Niagen Bioscience, Inc., side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CURLF | NAGE |
|---|---|---|
| Revenue | $1.3B | $129.4M |
| Net income | $-231.1M | $17.4M |
| Gross margin | 49.8% | 64.3% |
| Net margin | −18.0% | 13.4% |
| Return on equity | −28.6% | 28.3% |
| Diluted EPS | −$0.35 | $0.20 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $74.3M | — |
| Equity | $756.4M | $76.5M |
| Net debt / equity | 0.59× | — |
| Current ratio | 1.52× | 4.86× |
| Revenue CAGR 5y | — | 16.9% |
| Profit CAGR 5y | — | — |
CURLF bills 9.8× the revenue of NAGE, and CURLF closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
5 years side by side
| Fiscal year | CURLF | NAGE |
|---|---|---|
| FY2025 | $1.3B | $129.4M |
| FY2024 | $1.3B | $99.6M |
| FY2023 | $1.3B | $83.6M |
| FY2022 | $1.3B | $72.0M |
| FY2021 | $1.2B | $67.4M |
Net income by year
Bottom line
| Fiscal year | CURLF | NAGE |
|---|---|---|
| FY2025 | $-231.1M | $17.4M |
| FY2024 | $-215.4M | $8.6M |
| FY2023 | $-281.2M | $-4.9M |
| FY2022 | $-370.1M | $-16.5M |
| FY2021 | $-205.9M | $-27.1M |
More in this industry